236 related articles for article (PubMed ID: 17669010)
41. Solution to vaccine mystery starts to crystallize.
Leslie M
Science; 2013 Jul; 341(6141):26-7. PubMed ID: 23828925
[No Abstract] [Full Text] [Related]
42. Particulate delivery systems for vaccines: what can we expect?
Bramwell VW; Perrie Y
J Pharm Pharmacol; 2006 Jun; 58(6):717-28. PubMed ID: 16734973
[TBL] [Abstract][Full Text] [Related]
43. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators.
Nordly P; Madsen HB; Nielsen HM; Foged C
Expert Opin Drug Deliv; 2009 Jul; 6(7):657-72. PubMed ID: 19538037
[TBL] [Abstract][Full Text] [Related]
44. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.
Drane D; Gittleson C; Boyle J; Maraskovsky E
Expert Rev Vaccines; 2007 Oct; 6(5):761-72. PubMed ID: 17931156
[TBL] [Abstract][Full Text] [Related]
45. Mucosal immunity: overcoming the barrier for induction of proximal responses.
McKenzie BS; Brady JL; Lew AM
Immunol Res; 2004; 30(1):35-71. PubMed ID: 15258310
[TBL] [Abstract][Full Text] [Related]
46. Adjuvants and delivery systems in veterinary vaccinology: current state and future developments.
Heegaard PM; Dedieu L; Johnson N; Le Potier MF; Mockey M; Mutinelli F; Vahlenkamp T; Vascellari M; Sørensen NS
Arch Virol; 2011 Feb; 156(2):183-202. PubMed ID: 21170730
[TBL] [Abstract][Full Text] [Related]
47. ISCOMATRIX™ adjuvant reduces mucosal tolerance for effective pulmonary vaccination against influenza.
Timothy AA; Tokanovic A; Snibson KJ; Edwards SJ; Pearse MJ; Scheerlinck JP; Sutton P
Hum Vaccin Immunother; 2015; 11(2):377-85. PubMed ID: 25692970
[TBL] [Abstract][Full Text] [Related]
48. Virus-like particle vaccines and adjuvants: the HPV paradigm.
Buonaguro FM; Tornesello ML; Buonaguro L
Expert Rev Vaccines; 2009 Oct; 8(10):1379-98. PubMed ID: 19803760
[TBL] [Abstract][Full Text] [Related]
49. Delivery systems: a vaccine strategy for overcoming mucosal tolerance?
Mann JF; Acevedo R; Campo JD; Pérez O; Ferro VA
Expert Rev Vaccines; 2009 Jan; 8(1):103-12. PubMed ID: 19093777
[TBL] [Abstract][Full Text] [Related]
50. Advances and challenges in mucosal adjuvant technology.
Newsted D; Fallahi F; Golshani A; Azizi A
Vaccine; 2015 May; 33(21):2399-405. PubMed ID: 25865473
[TBL] [Abstract][Full Text] [Related]
51. Saponins from the Spanish saffron Crocus sativus are efficient adjuvants for protein-based vaccines.
Castro-Díaz N; Salaun B; Perret R; Sierro S; Romero JF; Fernández JA; Rubio-Moraga A; Romero P
Vaccine; 2012 Jan; 30(2):388-97. PubMed ID: 22079266
[TBL] [Abstract][Full Text] [Related]
52. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
[TBL] [Abstract][Full Text] [Related]
53. Generation and maintenance of mucosal memory B cell responses?
Vajdy M
Curr Med Chem; 2006; 13(25):3023-37. PubMed ID: 17073644
[TBL] [Abstract][Full Text] [Related]
54. Novel Th1-biased adjuvant, SPO1, enhances mucosal and systemic immunogenicity of vaccines administered intranasally in mice.
Yu S; Tang C; Shi X; Yang P; Xing L; Wang X
Vaccine; 2012 Aug; 30(36):5425-36. PubMed ID: 22709954
[TBL] [Abstract][Full Text] [Related]
55. ISCOMATRIX adjuvant for antigen delivery.
Pearse MJ; Drane D
Adv Drug Deliv Rev; 2005 Jan; 57(3):465-74. PubMed ID: 15560952
[TBL] [Abstract][Full Text] [Related]
56. Modulation of immune responses - strategies for optimising vaccines.
Dumont AR; Kalfayan LH; Sékaly RP
Expert Opin Biol Ther; 2004 May; 4(5):627-30. PubMed ID: 15155154
[TBL] [Abstract][Full Text] [Related]
57. Bacterial ghosts as adjuvant particles.
Riedmann EM; Kyd JM; Cripps AW; Lubitz W
Expert Rev Vaccines; 2007 Apr; 6(2):241-53. PubMed ID: 17408373
[TBL] [Abstract][Full Text] [Related]
58. Adjuvants: Classification, Modus Operandi, and Licensing.
Apostólico Jde S; Lunardelli VA; Coirada FC; Boscardin SB; Rosa DS
J Immunol Res; 2016; 2016():1459394. PubMed ID: 27274998
[TBL] [Abstract][Full Text] [Related]
59. Beyond empiricism: informing vaccine development through innate immunity research.
Levitz SM; Golenbock DT
Cell; 2012 Mar; 148(6):1284-92. PubMed ID: 22424235
[TBL] [Abstract][Full Text] [Related]
60. Current vaccine adjuvants: an overview of a diverse class.
Kensil CR; Mo AX; Truneh A
Front Biosci; 2004 Sep; 9():2972-88. PubMed ID: 15353330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
